PT1309559E - Derivados de 4-fenil-piridina como antagonistas do receptor de neuroquinina-1 - Google Patents
Derivados de 4-fenil-piridina como antagonistas do receptor de neuroquinina-1Info
- Publication number
- PT1309559E PT1309559E PT01980219T PT01980219T PT1309559E PT 1309559 E PT1309559 E PT 1309559E PT 01980219 T PT01980219 T PT 01980219T PT 01980219 T PT01980219 T PT 01980219T PT 1309559 E PT1309559 E PT 1309559E
- Authority
- PT
- Portugal
- Prior art keywords
- neuroquinin
- receptor antagonists
- pyridine derivatives
- phenyl pyridine
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00117003 | 2000-08-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1309559E true PT1309559E (pt) | 2006-10-31 |
Family
ID=8169466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT01980219T PT1309559E (pt) | 2000-08-08 | 2001-07-27 | Derivados de 4-fenil-piridina como antagonistas do receptor de neuroquinina-1 |
Country Status (37)
Country | Link |
---|---|
US (1) | US6770637B2 (pt) |
EP (1) | EP1309559B1 (pt) |
JP (1) | JP4053877B2 (pt) |
KR (1) | KR100518201B1 (pt) |
CN (1) | CN1293056C (pt) |
AR (1) | AR030324A1 (pt) |
AT (1) | ATE328871T1 (pt) |
AU (2) | AU2002212118B2 (pt) |
BR (1) | BR0113173A (pt) |
CA (1) | CA2418868C (pt) |
CZ (1) | CZ2003684A3 (pt) |
DE (1) | DE60120419T2 (pt) |
DK (1) | DK1309559T3 (pt) |
EC (1) | ECSP034475A (pt) |
ES (1) | ES2264706T3 (pt) |
GT (1) | GT200100160A (pt) |
HK (1) | HK1076459A1 (pt) |
HR (1) | HRP20030055A2 (pt) |
HU (1) | HUP0301671A3 (pt) |
IL (2) | IL154079A0 (pt) |
JO (1) | JO2371B1 (pt) |
MA (1) | MA27680A1 (pt) |
MX (1) | MXPA03001143A (pt) |
MY (1) | MY128993A (pt) |
NO (1) | NO324841B1 (pt) |
NZ (1) | NZ523751A (pt) |
PA (1) | PA8524401A1 (pt) |
PE (1) | PE20020332A1 (pt) |
PL (1) | PL359849A1 (pt) |
PT (1) | PT1309559E (pt) |
RU (1) | RU2277087C2 (pt) |
SI (1) | SI1309559T1 (pt) |
TW (1) | TWI259180B (pt) |
UY (1) | UY26872A1 (pt) |
WO (1) | WO2002016324A1 (pt) |
YU (1) | YU8703A (pt) |
ZA (1) | ZA200300614B (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1103545T3 (da) * | 1999-11-29 | 2004-03-15 | Hoffmann La Roche | 2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide |
EP1688408A3 (en) * | 2002-08-08 | 2007-08-22 | Amgen, Inc | Vanilloid receptor ligands and their use in treatments |
KR20050055694A (ko) | 2002-08-08 | 2005-06-13 | 암젠 인코포레이티드 | 바닐로이드 수용체 리간드 및 치료시 이들의 용도 |
WO2005000247A2 (en) * | 2003-06-25 | 2005-01-06 | Smithkline Beecham Corporation | 4-carboxamido quinoline derivatives for use as nk-2 and nk-3 |
WO2005002577A1 (en) | 2003-07-03 | 2005-01-13 | F. Hoffmann-La Roche Ag | Dual nk1/nk3 antagonists for treating schizophrenia |
MY139645A (en) | 2004-02-11 | 2009-10-30 | Amgen Inc | Vanilloid receptor ligands and their use in treatments |
WO2005077938A1 (en) | 2004-02-11 | 2005-08-25 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
WO2006014168A1 (en) * | 2004-07-06 | 2006-02-09 | Xenon Pharmaceuticals Inc. | Nicotinamide derivatives and their use as therapeutic agents |
KR100881240B1 (ko) * | 2004-07-06 | 2009-02-05 | 에프. 호프만-라 로슈 아게 | Nk-1 수용체 길항제의 합성에 있어서 중간체로서사용되는 카르복스아미드 피리딘 유도체의 제조 방법 |
EP1776342B1 (en) * | 2004-07-06 | 2011-03-02 | F. Hoffmann-La Roche AG | Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists |
US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
US7301022B2 (en) | 2005-02-15 | 2007-11-27 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
KR20070094666A (ko) | 2005-02-25 | 2007-09-20 | 에프. 호프만-라 로슈 아게 | 약제 물질 분산성이 향상된 정제 |
EP1879881A2 (en) * | 2005-04-14 | 2008-01-23 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
MX2008002019A (es) * | 2005-08-11 | 2008-04-16 | Vertex Pharma | Moduladores del regulador de conductancia transmembrana de fibrosis quistica. |
CA2621564C (en) | 2005-09-09 | 2014-06-03 | Smithkline Beecham Corporation | Pyridine derivatives and their use in the treatment of psychotic disorders |
SI2404919T1 (sl) | 2005-11-08 | 2013-12-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
MX2008012945A (es) | 2006-04-07 | 2009-01-15 | Vertex Pharma | Moduladores de transportadores de cartucho de union a adenosina-trifosfato celular (atp). |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
CA2676357A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
CA2686838C (en) | 2007-05-09 | 2017-03-14 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
UY31272A1 (es) * | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
CA2706920C (en) | 2007-12-07 | 2018-02-13 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
PT2639222T (pt) | 2007-12-07 | 2016-11-01 | Vertex Pharma | Processo de produção de ácidos cicloalquilcarboxamido-piridina-benzoicos |
ES2647531T3 (es) | 2008-02-28 | 2017-12-22 | Vertex Pharmaceuticals Incorporated | Derivados de heteroarilo como moduladores de CFTR |
GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
UA107088C2 (xx) * | 2009-09-11 | 2014-11-25 | 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину | |
WO2011054773A1 (en) | 2009-11-03 | 2011-05-12 | Glaxosmithkline Llc | Novel lactam compounds |
FR2954315B1 (fr) * | 2009-12-23 | 2012-02-24 | Galderma Res & Dev | Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
HRP20211752T1 (hr) | 2010-04-07 | 2022-02-18 | Vertex Pharmaceuticals Incorporated | Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena |
TWI549950B (zh) | 2010-04-07 | 2016-09-21 | 維泰克斯製藥公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧雜環戊烯-5-基)環丙烷甲醯胺基)-3-甲基吡啶-2-基)苯甲酸之固體形式 |
SG10201505700QA (en) | 2010-04-22 | 2015-08-28 | Vertex Pharma | Process of producing cycloalkylcarboxamido-indole compounds |
WO2013049559A1 (en) * | 2011-09-30 | 2013-04-04 | Endo Pharmaceuticals Inc. | Pyridine derivatives |
US8809372B2 (en) * | 2011-09-30 | 2014-08-19 | Asana Biosciences, Llc | Pyridine derivatives |
MX357328B (es) | 2011-11-08 | 2018-07-05 | Vertex Pharma | Moduladores de trasportadores de casete enlazante de atp. |
US9012496B2 (en) | 2012-07-16 | 2015-04-21 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
WO2015068744A1 (ja) * | 2013-11-08 | 2015-05-14 | キッセイ薬品工業株式会社 | カルボキシメチルピペリジン誘導体 |
PL3068392T3 (pl) | 2013-11-12 | 2021-07-19 | Vertex Pharmaceuticals Incorporated | Proces wytwarzania kompozycji farmaceutycznych do leczenia chorób, w których pośredniczy cftr |
SI3131582T1 (sl) | 2014-04-15 | 2018-09-28 | Vertex Pharmaceuticals Incorporated | Farmacevtski sestavki za zdravljenje bolezni, pri katerih posreduje regulator transmembranske prevodnosti |
TWI649307B (zh) * | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
JP6494757B2 (ja) | 2014-11-18 | 2019-04-03 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | ハイスループット試験高速液体クロマトグラフィーを行うプロセス |
WO2016149324A1 (en) * | 2015-03-16 | 2016-09-22 | Vanderbilt University | Negative allosteric modulators of metabotropic glutamate receptor 2 |
CN108712913B (zh) | 2015-12-22 | 2022-06-24 | 武田药品工业株式会社 | 内体g蛋白-偶联的受体的三部分调节剂 |
IL292921A (en) | 2019-11-15 | 2022-07-01 | Kandy Therapeutics Ltd | A new chemical process for the preparation of 6-chloro-4-(4-fluoro-2-methylphenyl)pyridine-3-amine a key intermediate of nt-814 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56106286A (en) | 1980-01-28 | 1981-08-24 | Nippon Musical Instruments Mfg | Electronic musical instrument |
EP0103545A3 (en) | 1982-09-13 | 1984-10-03 | Arc Technologies Systems, Ltd. | Electrode for arc furnaces |
US4745123A (en) * | 1986-02-18 | 1988-05-17 | Warner-Lambert Company | Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
JP3071467B2 (ja) | 1993-12-29 | 2000-07-31 | メルク シヤープ エンド ドーム リミテツド | 置換モルホリン誘導体およびその治療剤としての使用 |
TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
AR004735A1 (es) * | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. |
AU4885097A (en) * | 1996-11-08 | 1998-06-03 | Sankyo Company Limited | Arylureas or arylmethylcarbamoyl derivatives |
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
KR100514236B1 (ko) * | 1999-02-24 | 2005-09-13 | 에프. 호프만-라 로슈 아게 | 페닐 유도체 및 피리디닐 유도체 |
DK1394150T3 (da) * | 1999-02-24 | 2011-03-21 | Hoffmann La Roche | 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister |
EP1222800A2 (en) * | 1999-10-14 | 2002-07-17 | Telefonaktiebolaget LM Ericsson (publ) | System and method of retrieving voice mail messages in a telecommunications network |
US6303790B1 (en) * | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
DK1103545T3 (da) * | 1999-11-29 | 2004-03-15 | Hoffmann La Roche | 2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide |
-
2001
- 2001-07-26 TW TW090118253A patent/TWI259180B/zh not_active IP Right Cessation
- 2001-07-27 CA CA002418868A patent/CA2418868C/en not_active Expired - Lifetime
- 2001-07-27 PT PT01980219T patent/PT1309559E/pt unknown
- 2001-07-27 AU AU2002212118A patent/AU2002212118B2/en not_active Ceased
- 2001-07-27 YU YU8703A patent/YU8703A/sh unknown
- 2001-07-27 DE DE60120419T patent/DE60120419T2/de not_active Expired - Lifetime
- 2001-07-27 SI SI200130577T patent/SI1309559T1/sl unknown
- 2001-07-27 HU HU0301671A patent/HUP0301671A3/hu not_active Application Discontinuation
- 2001-07-27 CN CNB018153364A patent/CN1293056C/zh not_active Expired - Lifetime
- 2001-07-27 KR KR10-2003-7001838A patent/KR100518201B1/ko active IP Right Grant
- 2001-07-27 DK DK01980219T patent/DK1309559T3/da active
- 2001-07-27 AU AU1211802A patent/AU1211802A/xx active Pending
- 2001-07-27 MX MXPA03001143A patent/MXPA03001143A/es active IP Right Grant
- 2001-07-27 BR BR0113173-7A patent/BR0113173A/pt not_active Application Discontinuation
- 2001-07-27 JP JP2002521200A patent/JP4053877B2/ja not_active Expired - Lifetime
- 2001-07-27 EP EP01980219A patent/EP1309559B1/en not_active Expired - Lifetime
- 2001-07-27 PL PL35984901A patent/PL359849A1/xx not_active Application Discontinuation
- 2001-07-27 AT AT01980219T patent/ATE328871T1/de active
- 2001-07-27 CZ CZ2003684A patent/CZ2003684A3/cs unknown
- 2001-07-27 ES ES01980219T patent/ES2264706T3/es not_active Expired - Lifetime
- 2001-07-27 WO PCT/EP2001/008686 patent/WO2002016324A1/en active IP Right Grant
- 2001-07-27 IL IL15407901A patent/IL154079A0/xx active IP Right Grant
- 2001-07-27 NZ NZ523751A patent/NZ523751A/en unknown
- 2001-07-27 RU RU2003105805/04A patent/RU2277087C2/ru not_active IP Right Cessation
- 2001-08-03 US US09/922,066 patent/US6770637B2/en not_active Expired - Lifetime
- 2001-08-05 JO JO2001130A patent/JO2371B1/en active
- 2001-08-06 PA PA20018524401A patent/PA8524401A1/es unknown
- 2001-08-06 AR ARP010103749A patent/AR030324A1/es not_active Application Discontinuation
- 2001-08-06 PE PE2001000779A patent/PE20020332A1/es not_active Application Discontinuation
- 2001-08-06 MY MYPI20013680A patent/MY128993A/en unknown
- 2001-08-07 GT GT200100160A patent/GT200100160A/es unknown
- 2001-08-07 UY UY26872A patent/UY26872A1/es not_active Application Discontinuation
-
2003
- 2003-01-22 IL IL154079A patent/IL154079A/en not_active IP Right Cessation
- 2003-01-22 ZA ZA200300614A patent/ZA200300614B/en unknown
- 2003-01-27 HR HR20030055A patent/HRP20030055A2/xx not_active Application Discontinuation
- 2003-02-05 MA MA27029A patent/MA27680A1/fr unknown
- 2003-02-07 NO NO20030632A patent/NO324841B1/no unknown
- 2003-02-07 EC EC2003004475A patent/ECSP034475A/es unknown
-
2005
- 2005-09-23 HK HK05108388A patent/HK1076459A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1309559E (pt) | Derivados de 4-fenil-piridina como antagonistas do receptor de neuroquinina-1 | |
PT1305319E (pt) | Derivados de 4-fenil-piridina como antagonistas do receptor da neuroquinina-1 | |
PT1349839E (pt) | Derivados de feniletenilo ou feniletinilo como antagonistas do receptor de glutamato | |
PT1224175E (pt) | Derivados de benzodiazepina como antagonistas do receptor de glutamato metabotropico | |
PT1343786E (pt) | Novos derivados de pirazolopiridina substituidos por piridina | |
ATE368659T1 (de) | Thrombinrezeptorantagonisten | |
AR028621A1 (es) | Antagonistas receptores de adenosina a2a | |
PT1379511E (pt) | Derivados de di-hidro-benzo[b] [1,4] diazepin-2-ona como antagonistas ii de r2glum | |
CY2011002I1 (el) | N-πυρραζολικοι αγωνιστες του α2α υποδοχεα | |
PT1192169E (pt) | C-pirazoles agonistas do receptor a2a | |
DE60026169D1 (de) | Selektive neurokinin-antagonisten | |
DE60318697D1 (de) | Triazolderivate als tachykininrezeptor-antagonisten | |
AR028576A1 (es) | Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa | |
PT1224174E (pt) | Derivados de benzodiazepina como antagonistas do receptor metabotropico do glutamato | |
PT1198453E (pt) | Derivados de n-(indolcarbonil)-piperazina como ligandos do receptor 5-ht2a | |
PT1379522E (pt) | Derivados de di-hidro-benzo[b] [1,4] diazepina-2-ona como antagonistas i do r2glum | |
PT1216239E (pt) | Derivados de piperazina como antagonistas de 5-ht1b | |
AR028575A1 (es) | Derivados de pirrolopiridinona utiles como inhibidores de fosfodiesterasa | |
PT1421075E (pt) | Derivados de piperdina uteis como antagonistas do ccr5 | |
PT1192170E (pt) | Agonistas de receptor a2a de propargilfenileter | |
PT1226131E (pt) | Derivados de isoxazolecarboxamida como antagonistas do receptor adrenergico alfa1 | |
ATE432282T1 (de) | 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten | |
PT1360184E (pt) | Derivados de piperidina como antagonistas da neuroquinina 1 | |
NO20015779D0 (no) | Bradykinin-reseptorantagonister | |
DE60133931D1 (de) | Kondensierte purinderivate als a1-adenosinrezeptorantagonisten |